Switzerland-based pesticides maker Syngenta said on Wednesday that it has acquired a repository of natural compounds and ...

The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss ...

Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...

The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Emasan AG is offering around 26.5M shares in Swiss Novartis (NVS) through Goldman Sachs, potentially raising $3B, Pablo Mayo Cerqueiro of ...

FoRx Therapeutics appoints Dr. Jens Wurthner, PhD, as Chief Medical Officer and reports progress toward IND submission by mid ...

Prior to this announcement, Novartis' dividend was comfortably covered by both cash flow and earnings. This indicates that a ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF95.00.

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

(Bloomberg) -- Novartis AG’s Sandoz family is poised to sell a roughly 1.2% stake in the Swiss pharmaceutical group.